Abstract:Objective: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary. Methods: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed. The survival was calculated by Kaplan-Meier method and compared using the log-rank test. Results: The median age at diagnosis was 49 years (range, 28-73 years). The most common symptoms were abnormal vaginal bleeding (69.8%) and abdominal or pelvic pain (44.2%).Pelvic masses were found in 39.5% of the patients and enlarged corpus in 27.9% at physical examination, while pelvic masses were found in 67.4% of the 43 patients (29 cases) and thickening or abnormal endometrium in 23.3% (10 cases) during ultrasound examination. Of 25 patients examined by CT/MRI, pelvic masses were found in 13 cases and enlarged uterus in 11 cases. All 15 patients who underwent endometrial biopsies were proven to have endometrial carcinomas. Serum CA125 level was found to be elevated in 22 of the 34 examined cases (64.7%) with a median value of 500 U/ml (range, 39-3439 U/ml). FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases. Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas. Thirty-one patients underwent total hysterectomy plus bilateral salpingo-oophorectomy with omentectomy and appendectomy, meanwhile, 12 patients had pelvic lymph node dissection. Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma. The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%). Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment. The 3- and 5-year survival rates of the group were 87.4% and 71.1%, respectively. The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%). The 3-year and 5-year survival rates of patients with early stage disease were better than those of the other patients (93.3%, 93.3% vs. 69.7%, 36.7%). Recurrence developed in 15 patients (34.9%). It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors. Conclusion: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis. The impact of the CA125 level on prognosis needs to be further studied. Surgical treatment alone may be enough for early stage patients. Chemotherapy plus radiotherapy may be necessary for advanced stage patients.

Clinical Pathological Features and Prognosis of Endometrial Adenocarcinoma with Squamous Epithelial Differentiation in 46 Cases

A Clinicopathologic and Prognostic Analysis of 115 Cases of Endometrial Carcinoma

Endocervical Adenocarcinoma with Micropapillary Component, a Distinct Histological Subtype Associated with Aggressive Behavior and Poor Prognosis: A Clinicopathologic Study of 10 Patients

The prognostic value of squamous differentiation in endometrioid type endometrial cancer: a matched analysis

Endocervical adenocarcinomas classified by International Endocervical Adenocarcinoma Criteria and Classification: a clinicopathological and prognostic analysis of 286 cases

Pathological analysis of endometrial cancer combined with adenomyosis

[Clinicopathological Features of 67 Cases of Endometriosis-Associated Epithelial Ovarian Carcinoma.].

Accuracy of Tumor Grade by Preoperative Curettage and Associated Clinicopathologic Factors in Clinical Stage I Endometriod Adenocarcinoma

Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer

Characteristics and Related Factors of Recurrence and Metastasis of Advanced Endometrial Carcinoma

Clinical analysis of treatment outcome for 559 patients with endometrial cancer

Effect of endometriosis on prognosis of ovarian clear cell carcinoma: a 10-year retrospective study

A Clinical Analysis on the Prognosis and Its Related Factors of Advanced Endometrial Carcinoma

Malignant changes in adenomyosis in patients with endometrial adenocarcinoma: A case series

A Retrospective Comparative Study On Epithelial Ovarian Carcinomas Arising From And Concomitant With Endometriosis

A clinical analysis of the effects of adjuvant endocrine therapy for stage I endometrial carcinoma.

The clinical characteristics of high-grade urothelial carcinoma with squamous dif-ferentiation

Clinical analysis of treatment outcome for 435 patients with endometrial cancer

[Synchronous primary cancers of the endometrium and ovary: review of 43 cases]

[Clinical Significance of Adjuvant Endocrine Therapy in Treatment of Endometrial Carcinoma: Study of 171 Patients].

Study of molecular markers in patients with endometrial carcinoma and its prognosis on the effectiveness